Dr. Smith Discusses CAR T Cells in Multiple Myeloma

Video

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric androgen receptor (CAR) T-cell therapy in multiple myeloma.

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric androgen receptor (CAR) T-cell therapy in multiple myeloma.

The target of CAR T-cell therapy in multiple myeloma seems to be anti—B-cell maturation antigen (BCMA), says Smith. The investigational BCMA CAR T-cell therapy bb2121 had an objective response rate of 78% in patients with relapsed/refractory disease, according to interim findings of a phase I dose-escalation study (NCT02658929).

Smith says that next steps are going to include using a fully human CAR to minimize the potential immune responses against CAR.

Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.